Dr. Hendrix is a Professor of Medicine and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He has 25 years of experience in the design and conduct of translational clinical pharmacology studies, mostly of antiretroviral drugs for HIV treatment and prevention. He serves as Director of the Drug Development Unit in the Division of Clinical Pharmacology. His research focuses on development of antiretroviral drugs to prevent HIV infection. His HIV prevention research has been supported by CDC, NIH, USAID, the Bill and Melinda Gates Foundation, amfAR, and sponsors in the pharmaceutical industry.
Dr. Hendrix received his undergraduate degree in Applied Biology at MIT (1978) and his medical degree from Georgetown University, magna cum laude
(1984). He completed internship and residency in internal medicine on the Osler Medical Service, and fellowships in Infectious Diseases and Clinical Pharmacology at The Johns Hopkins Hospital. Before joining the Hopkins medical school faculty, Dr. Hendrix served on active duty for 10 years in the U.S. Air Force (USAF) where he was Director of the Air Force HIV Research and Education Program while assigned to Wilford Hall USAF Medical Center in San Antonio, TX (1989-2004), and he developed HIV prevention education programs for the United States military, United Nations Department of Peacekeeping Operations, and other militaries worldwide while assigned to the Division of Retrovirology, Walter Reed Army Institute of Research (1994-1996) and attached to the USAF Surgeon General's Office (USAF Reserve, 1997-1999).
Currently, Dr. Hendrix serves as Director of the Drug Development Unit (DDU) which focuses on early phases of clinical drug development. The DDU is a core facility that provides support to Hopkins faculty to design, execute, and analyze clinical protocols across many therapeutic areas. DDU specializes in first in human, phase I pharmacokinetic, and phase II proof of concept studies. Dr. Hendrix's primary research focus the past decade has been chemoprevention of HIV infection which includes developing topical microbicides to prevent sexual transmission of HIV. The DDU has supported Dr. Hendrix's own research by performing key studies to understand distribution of HIV after sexual exposure, distribution of drugs within the female genital tract and colon, and the impact of microbicide vehicles on mucosal health and resistance to HIV infection.
Through the support services of the Clinical Pharmacology Analytical Laboratory (CPAL), also in the Division of Clinical Pharmacology, Dr. Hendrix has been actively involved in randomized controlled trials of drugs for pre-exposure prophylaxis (PrEP) of HIV. CPAL's work is integral to the Pharmacology Core function of the NIH-funded HIV Prevention Trials Network (HPTN) and the Microbicide Trials Network (MTN) and contributed directly to the FDA's licensure of Truvada® for prevention of HIV infection. For both the HPTN and MTN, Dr. Hendrix serves as Director of the Pharmacology Core Laboratory.
Mentoring and teaching medical students, graduate students, and post-doctoral fellows have long been his passion and integral to the success of his own research accomplishments. Dr. Hendrix is a recipient of the Johns Hopkins Alumni Association Excellence in Teaching Award and the David M. Levine Faculty Mentoring Award at Hopkins. Seen as an opportunity to inform faculty colleagues, he has served on the Hopkins institutional review board for the past 16 years.
Dr. Hendrix has served on the FDA Antiviral Drug Products Advisory Committee, the Board of Scientific Counselors for the National Center for Infectious Diseases, and the Board of the American Society of Clinical Pharmacology and Therapeutics.